atp128
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 22, 2019 (NCT04046445)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04046445 | Phase 1/Phase 2 (Phase 2) | Jul 22, 2019 | Amal Therapeutics, Boehringer Ingelheim, University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amal Therapeutics | For profit | 1 | 1 | 1 | 2019 |
| Boehringer Ingelheim | For profit | 1 | 0 | 1 | 2019 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1